Navigation Links
VIVUS Reports Topline Findings From FORTRESS
Date:12/21/2011

and Drug Administration, or FDA, to our resubmission of the New Drug Application, or NDA, for Qnexa for the treatment of obesity, including weight loss and maintenance of weight loss, recommended for obese patients (BMI >/=30 kg/m2), or overweight patients (BMI >/=27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity), with a contraindication that excludes the use of Qnexa by women of child-bearing potential; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the reliability of the electronic medical claims healthcare databases used in the FORTRESS study; the FDA's interpretation of and agreement with the information VIVUS submitted relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study (OB-305) and Sleep Apnea study (OB-204); that we may be required to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
2. VIVUS Resubmits Qnexa NDA to the FDA
3. VIVUS Provides Regulatory Update on QNEXA
4. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
5. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
6. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
7. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
8. VIVUS to Present at Three Upcoming Investor Conferences in March
9. VIVUS Provides Regulatory Update on QNEXA NDA
10. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
11. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... SM , the nation,s leader in medication monitoring solutions, ... M.D., as Chief Medical Officer. In this role, Smith ... healthcare providers, patients and managed care plans.   ... of healthcare companies that have provided him with experiences ... sides of Ameritox,s business. He most recently served as ...
(Date:10/17/2014)... 17, 2014   ndd Medical Technologies , a ... precise ultrasound technology, announced that its EasyOne Pro® is ... Center , a 140,000 square foot, 44-bed hospital with ... hospital serves a large number of Native Americans ... and beyond. A portion of its funding ...
(Date:10/17/2014)... Calif. , Oct. 17, 2014  STAAR Surgical Company ... of implantable lenses and delivery systems for the eye, today ... Investor Breakfast Meeting on Saturday, October 18, 7:00 a.m. CT ... Chicago, IL. Dr. ... Eye Centre in Antwerp, Belgium , will ...
Breaking Medicine Technology:Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 2STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting 3
... VIEW, Calif., May 1, 2012 MAP Pharmaceuticals, Inc. (Nasdaq: ... the following investor conferences in May 2012: Deutsche Bank ... in Boston Bank of America Merrill Lynch 2012 Healthcare ... A live webcast of each event will be available ...
... May 1, 2012 /PRNewswire-iReach/ -- GenWay Biotech ... company,s new Vice President of GenWay Custom/OEM. This position ... focus on growth of the individual divisions including GenWay ... Biotech has provided the diagnostic and research communities with ...
Cached Medicine Technology:GenWay Biotech Appoints New Vice President of Custom/OEM 2GenWay Biotech Appoints New Vice President of Custom/OEM 3
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has ... GreenGeeks are the best Dedicated Server Hosting suppliers. ... want to buy high quality hosting and save ... manager of Top10BestSEOHosting.com says, “We believe that iPage ... everyone. A lot of the global clients enjoy ...
(Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Stephen T. Greenberg, ... been nominated for the 10th consecutive year as one of ... Dr. Greenberg was also been nominated as the best provider ... also nominated as best Day Spa and best Laser Treatment ... December 14th and readers can vote for the contest once ...
(Date:10/19/2014)... 20, 2014 – The U.S. Government has initiated ... Alzheimer,s disease by 2025. However, a workgroup of ... research milestones in the U.S. Government,s National Plan ... scope, increased in scale, and adequately funded in ... of proposals by the workgroup to enlarge and ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... Thermage, Inc.,(Nasdaq: THRM ), today announced ... Medical, Ltd., a leading distributor of advanced aesthetic,technology ... sales professionals will market the Company,s ThermaCool(R) systems,and ... United States. "We are very pleased to ...
... ... Brussels, HUNTERSVILLE, N.C., Oct. ... it has,acquired the rights to all of the intellectual property related to ... and back pain suffered by,individuals with lumbar spinal stenosis (LSS). The innovative ...
... In people with chronic myeloid leukemia (CML), the drug ... but the disease often returns when treatment is stopped. ... could cure CML under certain circumstances if it is ... Mathematician Natalia Komarova and biologist Dominik Wodarz also developed ...
... Majority Leader Harry Reid issued the following statement this,afternoon ... legislation:, "This afternoon, the Congress sent to President ... nation,s children. It is our hope and the will,of ... bill into law on,behalf of the future. It is ...
... Oct. 2 CYNACON/OCuSOFT (OCuSOFT,Inc.), a company ... ophthalmologists and optometrists, is pleased to announce ... its Optometric Scientific,Advisory Board. *(LOGO: Send2Press.com/mediaboom/07-0803-Occusoft_72dpi.jpg) ... of Omni Eye Surgery in New York,City. ...
... 3 With declining revenues and,shrinking sales forces, ... Affairs, to maximize their sales support role, yet ... goal, leading pharmaceutical,companies run sleek and efficient Medical ... function, thereby ensuring the creation of,winning products. ...
Cached Medicine News:Health News:Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd. 2Health News:Orthofix International Acquires InSWing(TM) Interspinous Process Spacer 2Health News:Orthofix International Acquires InSWing(TM) Interspinous Process Spacer 3Health News:Drug has ability to cure type of leukemia 2Health News:Medical Affairs: Building Efficient Medical Affairs Functions That Drive Product Marketing Success 2
Bravo Datalink. For upload of Bravo pH data to a PC. Connects to the pcs serial port....
Bravo Calibration Tubes...
pH Calibration Stand with two Sealable Buffer Tubes 1 set....
... catheters are efficient, economical, eliminate the ... patient comfort during the test period., ... have been designed to use temperature ... room-temperature calibration. The temperature correction factors ...
Medicine Products: